Policy Criteria Changes
Summary
Arkansas Blue Cross updated coverage criteria for Tislelizumab-jsgr (Tevimbra) to include FDA-labeled gastric cancer indication and revised off-label uses. Belantamab mafodotin-blmf (Blenrep) policy will be archived as HCPCS code J9037 becomes inactive March 31, 2025.
Get alerts when payers change rules like this one
We check Arkansas Blue Cross Blue Shield and other payers every day and email you when a change matches your specialty and state.